Chemical: Drug
butabarbital

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Generic Names
  • Butabarbital Sodium
  • Butabarbitone
  • Butrate
  • Secbubarbital
  • Secbutabarbital
  • Secbutobarbital
  • Secbutobarbitone
  • Sodium Butabarbital
Trade Names
  • Butabarb
  • Butalan
  • Butatab
  • Butatal
  • Buticaps
  • Butisol
  • Butisol Sodium
  • Medarsed
  • Nilox
  • Sarisol
  • Sarisol No. 1
  • Unicelles
Brand Mixture Names

PharmGKB Accession Id

PA164743463

Type(s):

Drug

Description

Butabarbital (trade name Butisol) is a prescription barbiturate sleep aid. Butabarbital has a particularly fast onset of effects and short duration of action compared to other barbiturates, which makes it useful for certain applications such as treating severe insomnia and relieving anxiety before surgical procedures; however it is also relatively dangerous particularly when combined with alcohol, and so is now rarely used, although it is still prescribed in some Eastern European and South American countries. Its short duration of action gives butabarbital a high abuse potential, comparable to secobarbital. Wikipedia

Source: Drug Bank

Indication

For short-term treatment of insomnia and anxiety disorders

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Butabarbital binds at a distinct binding site associated with a Cl - ionopore at the GABA A receptor, increasing the duration of time for which the Cl - ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.

Source: Drug Bank

Pharmacology

Butabarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Toxicity

Signs of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).

Source: Drug Bank

Route of Elimination

Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and most metabolic products are excreted in the urine.

Source: Drug Bank

Chemical Properties

Chemical Formula

C10H16N2O3

Source: Drug Bank

Isomeric SMILES

CC[C@H](C)C1(C(=O)NC(=O)NC1=O)CC

Source: Drug Bank

CCC(C)C1(CC)C(=O)NC(=O)NC1=O

Source: Drug Bank

Canonical SMILES

CCC(C)C1(CC)C(=O)NC(=O)NC1=O

Source: Drug Bank

Average Molecular Weight

212.2456

Source: Drug Bank

Monoisotopic Molecular Weight

212.116092388

Source: Drug Bank

SMILES

CCC(C)C1(CC)C(=O)NC(=O)NC1=O

Source: Drug Bank

InChI String

InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
CHRNA4 (source: Drug Bank)
CHRNA7 (source: Drug Bank)
GABRA1 (source: Drug Bank)
GABRA2 (source: Drug Bank)
GABRA3 (source: Drug Bank)
GABRA4 (source: Drug Bank)
GABRA5 (source: Drug Bank)
GABRA6 (source: Drug Bank)
GRIA2 (source: Drug Bank)
GRIK2 (source: Drug Bank)

Drug Interactions

Interaction Description
aminophylline - butabarbital The barbiturate, butabarbital, decreases the effect of aminophylline. (source: Drug Bank)
betamethasone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone. (source: Drug Bank)
clomifene - butabarbital The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene. (source: Drug Bank)
cyclosporine - butabarbital The barbiturate, butabarbital, increases the effect of cyclosporine. (source: Drug Bank)
dexamethasone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
diethylstilbestrol - butabarbital The enzyme inducer, butabarbital, decreases the effect of the hormone agent, diethylstilbestrol. (source: Drug Bank)
divalproex sodium - butabarbital Divalproex sodium increases the effect of the barbiturate, butabarbital. (source: Drug Bank)
doxycycline - butabarbital The anticonvulsant, butabarbital, decreases the effect of doxycycline. (source: Drug Bank)
estradiol - butabarbital The enzyme inducer decreases the effect of hormones (source: Drug Bank)
estradiol - butabarbital The enzyme inducer, butabarbital, decreases the effect of the hormone agent, estradiol. (source: Drug Bank)
ethinyl estradiol - butabarbital This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
felodipine - butabarbital The barbiturate, butabarbital, decreases the effect of felodipine. (source: Drug Bank)
fludrocortisone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone. (source: Drug Bank)
folic acid - butabarbital Folic acid decreases the effect of anticonvulsant, butabarbital. (source: Drug Bank)
gefitinib - butabarbital The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib. (source: Drug Bank)
griseofulvin - butabarbital The barbiturate, butabarbital, decreases the effect of griseofulvin. (source: Drug Bank)
hydrocortisone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank)
levonorgestrel - butabarbital Phenobarbital decreases the effect of levonorgestrel (source: Drug Bank)
medroxyprogesterone - butabarbital The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone. (source: Drug Bank)
megestrol - butabarbital The enzyme inducer, butabarbital, decreases the effect of the hormone agent, megestrol. (source: Drug Bank)
methadone - butabarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - butabarbital The barbiturate, butabarbital, decreases the effect of methadone. (source: Drug Bank)
metoprolol - butabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metoprolol - butabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
metronidazole - butabarbital The barbiturate, butabarbital, decreases the effect of metronidazole. (source: Drug Bank)
nifedipine - butabarbital The barbiturate decreases the effect of the calcium channel blocker (source: Drug Bank)
nifedipine - butabarbital The barbiturate, butabarbital, decreases the effect of the calcium channel blocker, nifedipine. (source: Drug Bank)
norethindrone - butabarbital This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
oxtriphylline - butabarbital The barbiturate, butabarbital, decreases the effect of oxtriphylline. (source: Drug Bank)
prednisolone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone. (source: Drug Bank)
prednisone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone. (source: Drug Bank)
propranolol - butabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
propranolol - butabarbital The barbiturate decreases the effect of metabolized beta-blocker (source: Drug Bank)
quinidine - butabarbital The anticonvulsant decreases the effect of quinidine (source: Drug Bank)
quinidine - butabarbital The anticonvulsant, butabarbital, decreases the effect of quinidine. (source: Drug Bank)
theophylline - butabarbital The barbiturate decreases the effect of theophylline (source: Drug Bank)
theophylline - butabarbital The barbiturate, butabarbital, decreases the effect of theophylline. (source: Drug Bank)
triamcinolone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone. (source: Drug Bank)
trimipramine - butabarbital The barbiturate, Butabarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butabarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. (source: Drug Bank)
triprolidine - butabarbital The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
triprolidine - butabarbital The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
verapamil - butabarbital Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed. (source: Drug Bank)
voriconazole - butabarbital Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated. (source: Drug Bank)
warfarin - butabarbital Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed. (source: Drug Bank)

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0037-0113-60
DrugBank:
DB00237
ChEBI:
3228
KEGG Compound:
C07827
KEGG Drug:
D03180
PubChem Compound:
2479
PubChem Substance:
10029
46505051
Drugs Product Database (DPD):
581291
ChemSpider:
2385
Therapeutic Targets Database:
DAP000667
FDA Drug Label at DailyMed:
7883bbc0-0874-11dc-a818-0002a5d5c51b

Clinical Trials

These are trials that mention butabarbital and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.